Alantra advises Optimus Holding Ltd on the acquisition of 100% of OM Pharma from Vifor Pharma
Value CHF 435 million
Zürich – Alantra is pleased to announce that it has advised Optimus Holding Ltd, a Swiss Group founded by a well-known Swiss business leader Etienne Jornod together with the Turkish pharmaceutical company Abdi Ibrahim and long-standing Swiss entrepreneurs, on the acquisition of 100% of the shares in OM Pharma, a Geneva-based company mainly active in the field of microbial derived immunotherapeutics, from Vifor Pharma [SWX:VIFN].
The acquisition of 100% of the share capital amounts to MCHF 435 and includes an earn out related to potential future value gains on 20% of Optimus Holding Ltd. Equity, which could increase the total transaction value in excess of MCHF 500, to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple. Completion is expected to take place in the following days.
Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.
Dec 2021Growth investmentDec 2021SECTOR HealthcareService Strategic Advisory
Dec 2021Debt Capital MarketsValue €230 millionDec 2021SECTOR HealthcareService Debt AdvisoryValue €230 million
Nov 2021Private placement and Equity raisingNov 2021SECTOR HealthcareService Equity Capital Markets
Nov 2021Sell-side advisoryValue $47.4 millionNov 2021SECTOR HealthcareService M&AValue $47.4 million